leisure time -WSS

leisure time

author：explore 2025-10-02 00:52:36 - browse：3861

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： ASCO: AstraZeneca says CAR

WSS

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Watch the official trailer for 'Ahsoka' series

Superbugs, antibiotic resistance get scrutiny in congress

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

EU fines Illumina $475 million over Grail acquisition

knowledge

leisure time

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Woman returns to dialysis after doctors remove transplanted pig kidney

Trump demands the U.S. pay no more for drugs than other countries … again

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

In age of alternative facts, a scholarly course on calling out crap

After half a century, Israel moves to evict squatter from his cave home on the beach

The high cost of giving birth even with insurance

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Hollywood unions extend contract negotiations for actors

How are insurers handling Leqembi and related scans?

hotspot

After half a century, Israel moves to evict squatter from his cave home on the beach

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Letters to First Opinion on caregivers, digital health, and more

Vermont grapples with historic flooding as more rainstorms head for Northeast

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

After half a century, Israel moves to evict squatter from his cave home on the beach

hotspot

leisure time

Wikipedia

knowledge